Answers are grounded in this paper and cite their sources.
The cost of CHB is variable both within and between European countries. The association of disease progression with increased cost of disease management suggests that measures to prevent or delay its progression would be economically beneficial.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: